<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Permanent <z:hpo ids='HP_0000572'>loss of vision</z:hpo> resulting from relapsing <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> occurs frequently in patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, despite intensive, <z:hpo ids='HP_0011010'>chronic</z:hpo> immunosuppressive therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Since <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) might have an important pathogenetic role in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, we decided to give a single infusion of infliximab-a monoclonal antibody against TNF-to five patients with relapsing <z:hpo ids='HP_0012121'>panuveitis</z:hpo>, at the immediate <z:hpo ids='HP_0003674'>onset</z:hpo> of last relapse </plain></SENT>
<SENT sid="2" pm="."><plain>Remission of <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> was evident within the first 24 h, and complete suppression was seen 7 days after treatment in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>No side-effects were noted </plain></SENT>
<SENT sid="4" pm="."><plain>We suggest that infliximab is a rapid and effective new therapy for sight-threatening <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> in <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease </plain></SENT>
</text></document>